Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids

BMC Genomics

Volumn 9, Issue , 2008, Pages

  L'Espérance, Sylvain ^a,b   Bachvarova, Magdalena ^b   Tetu, Bernard ^a,b   Mes Masson, Anne Marie ^c,d   Bachvarov, Dimcho ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; PACLITAXEL; TOPOTECAN; TUBULIN; ANTINEOPLASTIC AGENT;

ADAPTIVE IMMUNITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL ADHESION; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; DRUG EXPOSURE; DRUG MECHANISM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; LIPID METABOLISM; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; OVARY CANCER; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SPHEROID CELL; TRANSCRIPTION REGULATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETICS; MULTICELLULAR SPHEROID; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; SPHEROIDS, CELLULAR; TOPOTECAN;

EID: 41549112390     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-9-99     Document Type: Article

References (52)

1. Greenlee RT Hill-Harmon MB Murray T Thun M Cancer statistics 2001 CA Cancer J Clin 2001, 51:15-36. 11577478
2. du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R Wagner U 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 2005, 16(Suppl 8):vIii7-12. 10.1093/annonc/mdi961 16239238
3. Ozols RF Bundy BN Fowler J Clarke-Pearson D Mannel R Hartenback E Baergen R Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158) Proc Am Soc Clin Oncol 1999, 18:356a.
4. Markmon M Second-line chemotherapy of epithelial ovarian cancer Expert Rev Anticancer Ther 2003, 3:31-36. 10.1586/14737140.3.1.31 12597347
5. Moss C Kaye SB Ovarian cancer: Progress and continuing controversies in management Eur J Cancer 2002, 38:1701-1707. 10.1016/ S0959-8049(02)00161-2 12175685
6. Kita T Kikuchi Y Hirata J Nagata I Prognosis of ovarian cancer today Cancer J 1998. 11:201-207.
7. Goff BA Paley PJ Greer BE Gown AM Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma Gynecol Oncol 2001, 81(1):18-24. 10.1006/gyno.2000.6105 11277644
8. Hartmann LC Lu KH Linette GP Cliby WA Kalli KR Gershenson D Bast RC Stec J Iartchouk N Smith DI Ross JS Hoersch S Shridhar V Lillie J Kaufmann SH Clark EA Damokosh AI Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel CT Clin Cancer Res 2005, 11:2149-55. 10.1158/1078-0432.CCR-04-1673 15788660
9. Berchuck A Iversen ES Lancaster JM Pittman J Luo J Lee P Murphy S Dressman HK Febbo PG West M Nevins JR Marks JR Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers Clin Cancer Res 2005, 11:3686-3696. 10.1158/ 1078-0432.CCR-04-2398 15897565
10. Spentzos D Levine DA Kolia S Otu H Boyd J Libermann TA Cannistra SA Unique gene expression profile based on pathologic response in epithelial ovarian cancer J Clin Oncol 2005, 23:7911-7918. 10.1200/ JCO.2005.02.9363 16204010
11. Helleman J Jansen MP Span PN van Staveren IL Massuger LF Meijer-van Gelder ME Sweep FC Ewing PC van der Burg ME Stoter G Nooter K Berns EM Molecular profiling of platinum resistant ovarian cancer Int J Cancer 2006, 118:1963-1971. 10.1002/ijc.21599 16287073
12. Jazaeri AA Awtrey CS Chandramouli GV Chuang YE Khan J Sotiriou C Aprelikova O Yee CJ Zorn KK Birrer MJ Barrett JC Boyd J Gene Expression Profiles Associated with Response to CT in Epithelial Ovarian Cancers Clin Cancer Res 2005, 11:6300-6310. 10.1158/1078-0432.CCR-04-2682 16144934
13. Bachvarov D L'Espérance S Popa I Bachvarova M Plante M Têtu B Gene expression patterns of chemoresistant and chemosensitive ovarian serous adenocarcinomas with possible prognostic value in response to initial chemotherapy Int J Oncol 2006, 29:919-33. 16964388 apy
14. L'Espérance S Popa I Bachvarova M Plante M Patten N Wu L Têtu B Bachvarov D Gene expression profiling of paired tumor samples obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors Int J Oncol 2006, 29:5-24. 16773180
15. Sutherland R Cell and environment interaction in tumor microregions: The multicell spheroid model Science 1988, 240:177-184. 10.1126/ science.2451290 2451290
16. Desoize B Gimonet D Jardiller JC Cell culture as spheroids: An approach to multicellular resistance Anticancer Res 1998, 18:4147-4158. 9891460
17. Kerbel RS Rak J Kobayashi H Man MS St Croix B Graham CH Multicellular resistance: A new paradigm to explain aspects of acquired drug resistance of solid tumors Cold Spring Harb Symp Quant Biol 1994, 59:661-672. 7587127
18. Graham CH Kobayashi H Stankiewicz KS Man S Kapitain SJ Kerbel RS Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents J Natl Cancer Inst 1994, 86:975-982. 10.1093/jnci/86.13.975 8007019
19. Kobayashi H Man S Graham C Kapitain SJ Teicher BA Kerbel RS Acquired multicellular-mediated resistance to alkylating agents in cancer Proc Natl Acad Sci USA 1993, 90:3294-3298. 46286 8475071 10.1073/ pnas.90.8.3294
20. Fraser M Leung B Jahani-Asl A Yan X Thompson WE Tsang BK Chemoresistance in human ovarian cancer: The role of apoptotic regulators Reprod Biol Endocrinol 2003, 1;66-78. 270001 14609433 10.1186/1477-7827-1-66
21. Xing H Wang S Hu K Tao W Li J Gao Q Yang X Weng D Lu Y Ma D Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy J Cancer Res Clin Oncol 2005, 131(8):511-519. 10.1007/s00432-005-0677-9 15924242
22. LaRue KE Bradbury EM Freyer JP Differential regulation of cyclin-dependent kinase inhibitors in monolayer and spheroid cultures of tumorigenic and nontumorigenic fibroblasts Cancer Res 1998, 58(6):1305-1314. 9515820
23. Jeggo PA Lobrich M Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability DNA Repair (Amst) 2006, 5(9-10):1192-1198. 10.1016/j.dnarep.2006.05.011 16797253
24. Wiltshire T Senft J Wang Y Konat GW Wenger SL Reed E Wang W BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven Mol Pharmacol 2007, 71(4):1051-1060. 10.1124/ mol.106.029504 17229870
25. Mullan PB Gorski JJ Harkin DP BRCA1 - a good predictive marker of drug sensitivity in breast cancer treatment? Biochim Biophys Acta 2006, 1766(2):205-216. 16919882
26. Wiltshire T Senft J Wang Y Konat GW Wenger SL Reed E Wang W BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven Mol Pharmaco 2007, 71(4):1051-1060. 10.1124/ mol.106.029504
27. Wernyj RP Morin PJ Molecular mechanisms of platinum resistance: Still searching for the Achilles' heel Drug Resist Updat 2004, 7(4-5):227-232. 10.1016/j.drup.2004.08.002 15533760
28. Johnson SW Laub PB Beesley JS Ozols RF Hamilton TC Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines Cancer Res 1997, 57(5):850-856. 9041185
29. Rasheed ZA Rubin EH Mechanisms of resistance to topoisomerase I-targeting drugs Oncogene 2003, 22:7296-7304. 10.1038/sj.onc.1206935 14576839
30. Ferry KV Hamilton TC Johnson SW Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF Biochem Pharmacol 2000, 60:1305-1313. 10.1016/S0006-2952(00)00441-X 11008124
31. Fujita N Kataoka S Naito M Heike Y Boku N Nakajima M Tsuruo T Suppression of T-lymphoma cell apoptosis by monoclonal antibodies raised against cell surface adhesion molecules Cancer Res 1993, 53:5022-5027. 8402694
32. Bates RC Edwards NS Yates JD Spheroids and cell survival Crit Rev Oncol Hematol 2000, 36(2-3):61-74. 10.1016/S1040-8428(00)00077-9 11033297
33. Mozzetti S Ferlini C Concolino P Filippetti F Raspaglio G Prislei S Gallo D Martinelli E Ranelletti FO Ferrandina G Scambia G Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients Clin Cancer Res 2005, 11(1):298-305. 15671559
34. Gregory RE DeLisa AF Paclitaxel: A new antineoplastic agent for refractory ovarian cancer Clin Pharm 1993, 12(6):104-115.
35. Bates RC Buret A van Helden DF Horton MA Burns GF Apoptosis induced by inhibition of intercellular contact J Cell Biol 1994, 25:403-415. 10.1083/jcb.125.2.403
36. Frisch SM Francis H Disruption of epithelial cell-matrix interactions induces apoptosis J Cell Biol 1994, 124:619-626. 10.1083/jcb.124.4.619 8106557
37. Katz MS Therapy insight: Potential of statins for cancer chemoprevention and therapy Nat Clin Pract Oncol 2005, 2(2):82-89. 10.1038/ncponc0097 16264880
38. Green SK Karlsson MC Ravetch JV Kerbel RS Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: Implications for antibody-based therapeutics of cancer Cancer Res 2002, 62(23):6891-6900. 12460904
39. White DE Rayment JH Muller WJ Addressing the role of cell adhesion in tumor cell dormancy Cell Cycle 2006, 5(16):1756-1759. 16880738
40. Mousa SA Anti-integrin as novel drug-discovery targets: Potential therapeutic and diagnostic implications Curr Opin Chem Biol 2002, 6:534-541. 10.1016/S1367-5931(02)00350-2 12133730
41. Graham MA Riley RJ Kerr DJ Drug metabolism in carcinogenesis and cancer chemotherapy Pharmacol Ther 1991, 51(2):275-289. 10.1016/ 0163-7258(91)90083-X 1784632
42. Demark-Wahnefried W Hars V Conaway MR Havlin K Rimer BK McElveen G Winer EP Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy Am J Clin Nutr 1997, 65(5):1495-1501. 9129482
43. Beck SA Groundwater P Barton C Tisdale MJ Alterations in serum lipolytic activity of cancer patients with response to therapy Br J Cancer 1990, 62:822-825. 2245174
44. Gercel-Taylor C Doering DL Kraemer FB Taylor DD Aberrations in normal systemic lipid metabolism in ovarian cancer patients Gynecol Oncol 1996, 60:35-41. 10.1006/gyno.1996.0008 8557225
45. Pardali K Moustakas A Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer Biochim Biophys Acta 2007, 1775:121-62. 16904831
46. Bachman KE Park BH Duel nature of TGF-beta signaling: Tumor suppressor vs. tumor promoter Curr Opin Oncol 2005 17 1 49 54 10.1097/ 01.cco.0000143682.45316.ae 15608513
47. Kudelka AP Tresukosol D Edwards CL Freedman RS Levenback C Chantarawiroj P Gonzalez de Leon C Kim EE Madden T Wallin B Hord M Verschraegen C Raber M Kavanagh JJ Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma J Clin Oncol 1996, 14(5):1552-1557. 8622071
48. Provencher DM Lounis H Champoux L Tetrault M Manderson EN Wang JC Eydoux P Savoie R Tonin PN Mes-Masson AM Characterization of four novel epithelial ovarian cancer cell lines In Vitro Cell Dev Biol Anim 2000, 36(6):357-61. 10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2 10949993
49. Martin C Walker J Rothnie A Callaghan R The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models Brit J Cancer 2003, 89:1581-1589. 10.1038/sj.bjc.6601300 14562035
50. Ingenuity Pathway Analysis http://www.Ingenuity.com
51. Primer3 http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi
52. ImageJ http://rsb.info.nih.gov/ij/